A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
Recruiting in Palo Alto (17 mi)
+39 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: XOMA (US) LLC
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers
Research Team
Eligibility Criteria
Inclusion Criteria
Individuals who participated in a previous study of gevokizumab in PG
A clinical diagnosis of classic pyoderma gangrenosum
Contraceptive measures adequate to prevent pregnancy during the study
Treatment Details
Interventions
- gevokizumab (Monoclonal Antibodies)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: gevokizumabExperimental Treatment1 Intervention
Solution for subcutaneous injection
Find a Clinic Near You
Who Is Running the Clinical Trial?
XOMA (US) LLC
Lead Sponsor
Trials
28
Recruited
2,100+